Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,805.00+1.10%ETH$2,504.05+3.54%GOLD$4,434.40+0.61%OIL$99.22-3.18%
Smart Investors Daily
KT

NASDAQ · KTTA

Pasithea Therapeutics Corp.

Healthcare · Biotechnology

$0.54

Down-$0.03 (-5.21%)

Updated Sep 11, 2026, 1:14 PM

SID Score

4.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
8.37M
P/E ratio
-0
Dividend yield
0.00%
52-week range
$0.28 – $2.06
Volume
246.9K
Avg. volume
6.91M

Price performance

KTTA price history

1M range · 20 trading sessions · Daily adjusted prices

KTTA closed at $0.54 after 20 trading sessions, up 12.97% for the selected period.

Last close
$0.54
Period change
+12.97%
Period low
$0.47
Period high
$0.60
Daily close
View OHLC price history
KTTA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$0.5701$0.5759$0.52$0.54246.9K
Sep 9, 2026$0.5989$0.5989$0.5507$0.5697211.38K
Sep 8, 2026$0.587$0.60$0.5795$0.599267.31K
Sep 4, 2026$0.5804$0.5926$0.57$0.58222.7K
Sep 3, 2026$0.5801$0.5949$0.575$0.5804124.44K
Sep 2, 2026$0.56$0.595$0.5501$0.5803225.75K
Sep 1, 2026$0.5568$0.578$0.55$0.563216.41K
Aug 31, 2026$0.5731$0.586$0.55$0.574450.59K
Aug 28, 2026$0.574$0.6044$0.5344$0.56483.91K
Aug 27, 2026$0.5755$0.5771$0.5485$0.554566.96K
Aug 26, 2026$0.569$0.5799$0.531$0.5794.76K
Aug 25, 2026$0.5325$0.5711$0.5251$0.56223.84K
Aug 24, 2026$0.5232$0.573$0.49$0.505339.05K
Aug 21, 2026$0.489$0.5394$0.4799$0.5394302.67K
Aug 20, 2026$0.485$0.4874$0.47$0.47107.96K
Aug 19, 2026$0.498$0.5096$0.4881$0.4989.66K
Aug 18, 2026$0.5049$0.51$0.4837$0.4976105.24K
Aug 17, 2026$0.487$0.5123$0.44$0.478178.01K
Aug 14, 2026$0.478$0.4947$0.4764$0.480543.25K
Aug 13, 2026$0.4975$0.4976$0.4751$0.47856.8K

Latest KTTA news

The latest Smart Investors Daily articles mentioning KTTA.

Stock researchCompany · Overview

KTTA research

Overview

Company profile and research snapshot.

Company profile

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$3.00
Implied upside
—
Analysts
7
KTTA recent ratings
DateFirmRatingTarget
Jun 16, 2026HC Wainwright & Co.Buy—
Apr 20, 2026HC Wainwright & Co.Buy—
Dec 8, 2025HC Wainwright & Co.Buy—
Jul 10, 2023EF HuttonBuy—
Apr 3, 2023EF HuttonBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 21, 2026

Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026

-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October 23, 2026 -- Full abstract will be published on ESMO website per Congress’ standard embargo schedule MIAMI, July 21, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next

Yahoo · Jul 8, 2026

Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

July 16 in Boston, management will engage with investors and industry participants at the healthcare-focused event covering neuropsychiatry, neurodegeneration, neuromuscular disease, ophthalmology, and neuroimmunologyMIAMI, July 08, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor for the long-term treatment of chronic diseases including the neu

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By